AstraZeneca announces new CMS J-code assigned for IMFINZI®
On February 19th, 2019
AstraZeneca is pleased to announce that IMFINZI® (durvalumab) injection has been assigned a unique HCPCS code by the Centers for Medicare & Medicaid Services (CMS).
Effective for dates of services on or after January 1, 2019, J-Code J9173 can be used to identify IMFINZI® (durvalumab) when billing across settings of care as noted in the Medicare Program.
AstraZeneca is pleased to announce that IMFINZI® (durvalumab) injection has been assigned a unique HCPCS code by the Centers for Medicare & Medicaid Services (CMS).
Effective for dates of services on or after January 1, 2019, J-Code J9173 can be used to identify IMFINZI® (durvalumab) when billing across settings of care as noted in the Medicare Program.
No comments have been posted yet.